816 results about "Immunopotentiation" patented technology

The present invention provides immunosuppression compounds capable of inhibiting the programmed cell death 1 (PD1) signalling pathway. The present invention further provides peptide based compositions for treatment of cancer or treatment of infections via immunopotentiation caused by inhibition of immunosuppressive signaling induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient. Further, the invention provides an application of the compositions containing the peptide moieties for preventive and / or therapeutic agents for cancer, cancer metastasis, immunodeficiency, an infectious disease or the like and an application of peptide moieties as a testing or diagnostic agent or a research agent for such a disease.

The present invention provides immunosuppression compounds capable of inhibiting the programmed cell death 1 (PD1) signalling pathway. The present invention further provides peptide based compositions for treatment of cancer or treatment of infections via immunopotentiation caused by inhibition of immunosuppressive signaling induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient. Further, the invention provides an application of the compositions containing the peptide moieties for preventive and / or therapeutic agents for cancer, cancer metastasis, immunodeficiency, an infectious disease or the like and an application of peptide moieties as a testing or diagnostic agent or a research agent for such a disease.

Disclosed are immunopotentiating agents, and vaccines thereof, which enhance and / or otherwise modify immune responses, and method for their preparation and use in vivo. Immunopotentiating agents can be single agents that act directly, adjuvants added concurrently with the agents, or heteroconjugates wherein the immunopotentiating agent is chemically coupled to the compound against which an immune response is desired. Examples of immunopotentiating agents include monoclonal antibodies, such as anti-CD3, anti-CD2) and anti-CD5 antibodies, and proteins derived from microorganisms (e.g., enterotoxins) which activate T cells. The compounds against which an immune response can be generated, which may be the second component in a heteroconjugate, include compound from abnormal or diseased tissues such as tumors, or infectious agents, such as viruses, bacteria, fungi, protozoal or metozoal parasites, and can be obtained by natural or recombinant means. Methods of using the invention to prepare monoclonal antibodies are particularly disclosed.

A medicinal composition for treating pain resulting from an inflammatory response comprises at least one pain relieving and anti-inflammatory pharmaceutical and at least one nutraceutical in a pharmaceutically acceptable base. The pharmaceutical is preferably acetaminophen or a non-steroidal anti-inflammatory drug (NSAID). The nutraceutical is preferably an immune booster, an anti-oxidant, a liver protectant, or a joint relief agent. Methods of using these compositions to treat pain caused by inflammation are also disclosed.

Methods of stimulating an immune response and treating patients responsive thereto with 3,4-di(1H-indol-3-yl)-1H-pyrrole-2,5-diones, staurosporine analogs, derivatized pyridazines, chromen-4-ones, indolinones, quinazolines, nucleoside analogs, and other small molecules are disclosed. In a preferred embodiment benzopyrimidine derivatives such as ZD-6474, MLN-518, lapatinib, gefitinib or erlotinib are used.

The invention relates, in part, to a method of treating a subject comprising administering to the subject a low, immune enhancing of a mTOR inhibitor and an immune effector cell engineered to express a CAR.

The invention relates to diagnostic methods for assessing the need of a subject for treatment with an anti-oxidant, or alternatively, for determining the utilization efficiency and ultimate effectiveness of anti-oxidant therapy in subjects having been treated with antioxidants. More specifically, the methods of the present invention are particularly useful in prophylactic assessment of individuals at risk for developing diseases or conditions in which oxidative stress plays a role, such that an appropriate therapeutic regimen can be prescribed for that individual, thus leading to alternative therapies and / or life style changes. The invention further relates to methods for assessing the need for, the utilization efficiency and the effectiveness of therapy in subjects having received therapy with specific antioxidant and immune enhancing formulations. Kits are also provided for measuring the levels of markers of oxidative stress and immune cell numbers.

The invention relates to a Chinese herbal medicine biological feed additive for livestock and a preparation method of the Chinese herbal medicine biological feed additive. The prepared Chinese herbal medicine biological feed additive for the livestock comprises the following raw materials in percentage by mass: 20% of probiotics, 10% of an enzyme preparation, 50% of traditional Chinese medicines, 10% of amino acids, 4% of vitamins, 1% of micro elements, 1% of an immunopotentiator, 1% of bacitracin and 3% of glucose. The preparation method comprises the following steps: firstly carrying out expanding culture to revive the probiotics, fermenting the probiotics for 2 days so as to obtain probiotics fermentation liquor; placing the traditional Chinese medicines into the probiotics fermentation liquor for fermentation; and finally mixing the dried fermentation products with other raw materials so as to obtain the Chinese herbal medicine biological feed additive for the livestock. The prepared Chinese herbal medicine biological feed additive for the livestock disclosed by the invention has the advantages of improving the immunity, increasing the utilization rate of the feed, improving environment and the like.

The present invention provides Immunosuppressive compounds capable of inhibiting the programmed cell death 1 (PD1) signalling pathway. The present invention further provides peptide based compositions for treatment of cancer or treatment of infections via immunopotentiation caused by inhibition of immunosuppressive signalling induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient. Further, the invention provides pharmaceutical compositions comprising the Immunosuppressive peptide compounds or modified peptide moieties for preventive and / or therapeutic agents for cancer, cancer metastasis, immunodeficiency, an infectious disease or the like and an application of PD-1 or PD-L1 as a testing or diagnostic agent or a research agent for such a disease.

The present invention relates to cyclic peptidomimetic compounds as therapeutic agents capable of inhibiting the programmed cell death 1 (PD1) signalling pathway. The invention also relates to derivatives of the therapeutic agents. The invention also encompasses the use of the said therapeutic agents and derivatives for treatment of disorders via immunopotentiation comprising inhibition of immunosuppressive signal induced due to PD-1, PD-L1, or PD-L2 and therapies using them.

The present invention provides an improved and more efficient method for the purification of Beta glucan, mannan and manno-protein complexes or immuno-potentiating substances, directly from yeast. In addition, the present invention provides methods for the production of Beta glucan, mannan and manno-proteins for use in animal feed to (1) prepare and enhance the immune system to fight infections more effectively and efficiently, (2) increase resistance to and decrease duration of bacterial and viral infections, (3) allow producers to reduce or remove “growth promotion antibiotics” in feed systems, thus producing more naturally grown animals, (4) reduce or prevent the negative growth response normally associated with administration of live vaccines to animals and (4) other associated health benefits such as in the case of swine of increased piglet litter size and survivability for piglets after weaning when Sows fed this novel Beta glucan extract.

Disclosed is a method to recover an antigen presenting cells (APCs) and immune cells rich mixture (AIM) from peripheral blood mononuclear cells (PBMC) mobilized with one or more cell adhesion inhibitors for the preparation of an AIM vaccine or an AIM adoptive immunotherapy preparation. In addition, AIM mobilization can be enhanced by priming, simultaneously or in sequence, one or more of a combination of different chemical compounds, cytokines, hormones, growth factors, etc. The interaction of chemokines and chemokine receptors enable tumor cells attachment or in close proximity to antigen presenting cells and immune cells which possess similar receptors in a micro niche environment. Severing the chemokine / chemokine receptor linkage by a cell adhesion inhibitor will release these specifically primed cell mixtures into the peripheral blood. The collection of these cells from the peripheral blood has never been described and is the basis of this invention. AIM cells can either be used alone or better still, be induced into more target specific preparations with additions, modifications and incubation, pre or post cell adhesion inhibitors mobilization, with vaccines, different target specific antigens, peptides, chemotherapeutic agents, oncolytic viral therapeutic agents, cytokines, co-stimulatory molecules, anti-regulatory T cell therapeutic agents, anti-CTLA4, anti-PD1 molecules and other methodologies of immunological enhancement known to the art. The AIM vaccine or AIM adoptive immunotherapy preparation can then be used, but not limited to, the treatment of cancer and other diseases.

Production of paclitaxel and muramic acid dipeptide conjugale as immunopotentiator and its use are disclosed. The process is carried out by combination of solid-phase chemistry and liquid-phase chemistry. It improves water solubility of paclitaxel.

The invention belongs to the field of aquaculture or feed, relates to a aquaculture feed, and especially relates to an alga immunopotentiation compound feed for litopenaeus vannamei. The invention at first provides an immunity strengthening agent for litopenaeus vannamei feed, and the agent is obtained through enzymatic hydrolysis and fermentation of an alga composite. The alga composite is composed of following components in parts by dried weight: 40 to 50 parts of asparagus, 15 to 25 parts of enteromorpha, 10 to 20 parts of ulva lactuca, 5 to 15 parts of laver and 5 to 15 parts of undaria pinnatifida. The invention further prepares a compound feed for litopenaeus vannamei by utilizing the immunity strengthening agent. The alga immunity strengthening agent contains algae polysaccharide, which has the effect of strengthening animal immunity, acrylic acid, terpenes, brominated phenolic and some sulfocompounds, which have the antiseptic effect, and sulphated polysaccharide, which has the antivirus effect. The litopenaeus vannameis fed on the alga immunopotentiation compound feed have a strong anti-stress performance, the body's immunity ability is improved, survival rate is high and culture benefit is remarkable.

Modular nanoparticle vaccine compositions and methods of making and using the same have been developed. Modular nanoparticle vaccine compositions comprise an antigen encapsulated in a polymeric particle and adaptor elements which modularly couple functional elements to the particle. The modular design of these vaccine compositions, which involves flexible addition and subtraction of antigen, adjuvant, immune potentiators, molecular recognition and transport mediation elements, as well as intracellular uptake mediators, allows for exquisite control over variables that are important in optimizing an effective vaccine delivery system.

The invention relates to the technical field of fermentation engineering, and discloses a submerged fermentation technology of producing immunological enhancement active materials of inonotus obliquus. The submerged fermentation technology of producing the immunological enhancement active materials of the inonotus obliquus comprises the main steps of culture activation, culture liquid cultivation, submerged fermentation and preparation of the immunological enhancement active materials of the inonotus obliquus and the like. The optimized submerged fermentation technology of producing the immunological enhancement active materials of the inonotus obliquus is high in content of the obtained immunological enhancement active materials, and good in activity of the obtained immunological enhancement active materials, and the obtained immunological enhancement active materials are beneficial for industrial application.

The present invention provides an immunogenic composition comprising a DNA expression vector encoding both an immunopotentiating chemokine sequence as well as an immunogenic polypeptide sequence. Immunogenic polypeptide sequences are those of infectious agents or of cancerous cells. Also provided are methods of manufacturing various immunogenic compositions, and methods of using such compositions to treat cancer and infectious disease.

The present invention provides a process for producing isoprenoid compounds or proteins encoded by DNA using DNA that contains one or more of the DNA encoding proteins having activity to improve efficiency in the biosynthesis of isoprenoid compounds effective in pharmaceuticals for cardiac diseases, osteoporosis, homeostasis, prevention of cancer, and immunopotentiation, health food and anti-fouling paint products against barnacles; the DNA; the protein; and a method for screening a substance with antibiotic and weeding activities comprising screening a substance inhibiting enzymatic reaction on the non-mevalonate pathway.

Influenza vaccines containing insoluble particulate adjuvants have been found to elicit an IgG response that is primarily a TH2 response (IgG1). This response can be shifted towards a TH1 response (IgG2a) by including immunopotentiators in the compositions. Thus the invention provides an immunogenic composition comprising: (i) an influenza virus antigen; (ii) an insoluble particulate adjuvant; and (iii) a immunopotentiator.

The invention provides a nibea albiflora richardson larvae and juvenile microcapsule feed which is prepared from white fish meal, euphausiid meal, squid meal, fish protein hydrolysate, feed yeast, alpha-starch, soybean lecithin, papain, fish oil, composite vitamin, composite mineral substance, binder, immunopotentiator, phagostimulant and the like. By adopting the innovated prescription and processing process, the microcapsule feed can fulfill the requirement for nutrition of larvae and juvenile growth, has the advantages of comprehensive nutrition, good palatability, high water stability, low cost and the like, can be produced in batches, is convenient for storing, transporting and feeding, is suitable for industrial breeding production, and adopts a corresponding feeding method, so that the survival rate of nibea albiflora richardson is greatly improved, the shape of the nibea albiflora richardson is increase. The nibea albiflora richardson larvae and juvenile microcapsule feed is suitable for large-scale popularization and application.

The invention discloses a water-in-oil-in-water adjuvant vaccine and a preparation method thereof. The adjuvant vaccine is composed of an internal water phase, a middle oil phase used for cladding the internal water phase, and an external water phase for cladding the middle oil phase. The external water phase comprises: a composite surfactant, a hydrophilic surfactant and mormal saline. The middle oil phase consists of: a lipophilic surfactant, a stabilizer and mineral oil. The internal water phase comprises: an immunopotentiator solution, the hydrophilic surfactant, and an inactivated antigen solution. The W / O / W (water-in-oil-in-water) type adjuvant vaccine provided in the invention can induce an immunoreaction earlier than traditional W / O (water-in-oil) type adjuvant vaccines, and can make experimental animals obtain earlier protective antibodies. The vaccine has good absorption, and causes a small inflammatory response at an inoculation site. The adjuvant vaccine disclosed in the invention has better stability than existing W / O / W type vaccines, and the antibody generation speed is fast.

The uses of mono acetyl diacyl glycerol derivatives extracted from deer antler for immunomodulating agent disclosed. Medical supplies and health foods containing the same as an effective ingredient also disclosed. Mono acetyl diacyl glycerol derivatives shows significantly effect for immuno modulation including immune enhancing. In the case of inducing cancer in a hamster by injecting cancer cell line, cancer development was delayed by activating lymphocytes, monocytes, and dendritic cells that are important factors to promote immunity and apoptosis of cancer cell was induced by promoting cytotoxicity of immune cell against cancer cell. Also in the case of mouse induced septic shock, it shows 100% survival rate even after lapse of 120 hours by control of immune function and suppression effect apoptosis. Therefore, mono acetyl diacyl glycerol derivatives according to the present invention can be effectively used for an immunomodulating agent, a sepsis treatment, a cancer treatment, and a health food for an immune modulation or the prevention of cancer.

The invention discloses a fermented Chinese herbal immunopotentiator used for snakeheads. With the efficacy of prevention, health care, treatment and immunoregulation, the Chinese herbal immunopotentiator is an ideal, green, environmental friendly, safe and novel feed additive for substituting antibiotic drugs. The fermented Chinese herbal feed additive is prepared by subjecting compound Chinese herbal medicines to a process of ''ultrasonic wave assisted extraction of Chinese herbal medicines and multi-strain two-step fermentation'', has the advantages of both Chinese herbal medicines and probiotics, can efficiently condition the intestinal health of snakeheads, treat both symptoms and root causes, consolidate the basis and foster vitality, maintain intestinal microecological balance and an optimal immune state, improves the digestibility of nutrients, improves the body immunity of snakeheads, improves farming profits, and reduces farming risk. The Chinese herbal immunopotentiator can be used for replacing antibiotics, has no adverse effect on snakeheads, is safe to use, and is free of drug residue, drug resistance and other problems, thus having broad market prospects.

Disclosed are a multipurpose, high-functional, alkaline solution composition, preparation therefor and use thereof as a nonspecific immunostimulator. The composition comprises 1-25 parts by weight of borax (Na2B4O7.10H2O), 10<-5>-10<-4 >parts by weight of sodium thiosulfate (Na2S2O3.5H2O), 30-150 parts by weight of potassium carbonate, 30-200 parts by weight of refined sugar (C12H22O11), and 100-200 parts by weight of water, based on 100 parts by weight of sodium metasilicate (Na2SiO3.5H2O). In addition to bringing about an improvement in disease resistance, weight gain rate, crop yield, crop quality, harvest time, the composition shows nonspecific immunostimulating activities, including antibody production and immune enhancement, by activating immune cells, thereby maximizing vaccination effects on malignant viral diseases.

The invention provides veterinary compound acanthopanax granules with immunopotentiation, which is prepared from the following Chinese medicament raw materials by weight percentage: 70 to 60 percent of acanthopanax and the balance of astragalus root, wherein 100 grams of granules contain 100 grams of crud drugs. The compound acanthopanax granules produced by the method have good stability and safety, are mainly applied to strengthening the immunological effect of a vaccine and strengthening the immunity of organisms and the anti-stress efficacy clinically, and is applied to treating various immunosuppressive diseases of chickens and other animals and birds, strengthening the immunological effect, and treating symptoms of hypoimmunity, inappetence and the like caused by transportations, groups changes, abrupt climate changes and the like.

Disclosed is a novel preparation of Thymosin alpha-1, which comprises Thymosin alpha-1, medicinal adjuvant and water for injection. The prepared Thymosin alpha-1 injection can be used as an immunity enhancement medicament for the treatment of chronic hepatitis B (HBV), hepatitis C (HCV), hepatocytecancer, melanocarcinoma, infectious disease, self-immune disease and malignant tumor.

The present invention provide a beta-1,3 / 1,6-glucan, a preparation method therefor, and application thereof in preparing immune enhancement and anti-tumor medicine and functional food. The preparation method comprises: drying and milling antarctic brown algae; after degreasing, water extracting, calcium chloride precipitating and anion exchanging resin purification, obtaining glucan with a beta-1,3-glucose main chain and a beta-1,6-glucose branched chain, wherein a molecular weight thereof is between 5-50 kDa. The beta-glucan prepared by the present invention has an immune enhancement activity, which is indicated by swallow of neutral red by in vitro macrophages and an NO release promoting experiment, and has a tumor growth inhibiting effect and a tumor metastasis inhibiting effect which are indicated by an in vivo animal experiment. According to the present invention, beta-1,3 / 1,6-glucan is prepared by using the antarctic brown algae; is characterized in richness and readily availability of raw material sources, simple preparation process, high product purity, strong bioactivity and easiness for industrialization; and has a prospect of being developed into immune enhancement and anti-tumor medicine.

The invention provides an immunity enhancing agent, an inactivated vaccine, and a preparation method thereof. The invention relates to the field of biopharmaceutical. The immunity enhancing agent comprises 0.1-21mg / mL of monophosphoryl lipid A, 1.5-125mg / mL of muramyl dipeptide, and 0.7-4.5mg / mL of beta-glucan. The invention also provides the inactivated vaccine comprising the immunity enhancing agent, and a preparation method of the inactivated vaccine. According to the invention, the immunity enhancing agent is mixed with an inactivated antigen solution, such that a water-phase solution is obtained; and the water-phase solution is mixed with an oil-phase solution, such that the inactivated vaccine is obtained. According to the immunity enhancing agent provided by the invention, with a synergetic effect of the components, body immunity level can be improved, and immune response to antigen can be improved, such that antibody level after immunization can be increased, immune window period can be shortened, and vaccine immunization effect can be enhanced. According to the inactivated vaccine comprising the immunity enhancing agent, antibody level after immunization is high, a protection period is long, and immunization window period is short.

The invention relates to a whole Luchuan pig feed capable of improving Luchuan pig feeding rewards. The whole Luchuan pig feed aims at overcoming the defects of short and small bodies, low growth speed and low feeding rewards of Luchuan pigs and can promote the growth and development and improve the immunity and digestion and absorption functions as well as infection resistance by improving nutritional components of the feed. The feed comprises the following raw materials: bean dregs, corn flour, potato powder, wheat middling, wheat flour, sorghum flour, rice flour, wheat bran, paddy meal, rice bran, calcium hydrophosphate, table salt, lysine and a premix, wherein the premix comprises living lactic acid bacteria, yeast autolysate, chelate metal trace elements, active calcium and phosphorus, fermentation type traditional Chinese medicine, complex vitamins, an immunopotentiator, mannan oligosaccharide and xylooligosaccharide. The cost unit price of the feed is about half of that of a traditional complete feed on the market, so that the breeding cost of pigs is lowered; the pigs can be slaughtered 15 days in advance, pig houses are free of odor, the pigs are healthy, and are low in morbidity, high in survival rate and good in meat quality and flavor, and the medical expense is reduced.

The invention relates to a 20S-protopanaxadiol beta-cyclodextrin inclusion compound which can be used for preparing medicines and foods for resisting tumors, protecting the liver, reducing blood fat, reducing blood sugar, promoting gastric secretion, promoting appetite, improving digestion functions, enhancing immunity, resisting oxidization and resisting senescence. The invention also relates toa preparation process as well as composition of the inclusion compound.